The combined selective advantage conferred by primary and secondary mutations defines the prevalence of substitutions at amino acid position 143 of HIV-1 integrase in raltegravir-resistant isolates

被引：0
|
作者：
Huang, W. [1 ]
Fransen, S. [1 ]
Frantzell, A. [1 ]
Petropoulos, C. J. [1 ]
机构：
[1] Monogram Biosci, San Francisco, CA USA
来源：
ANTIVIRAL THERAPY | 2011年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
47
引用
收藏
页码：A60 / A60
页数：1
相关论文
共 6 条
  • [1] Multiple Genetic Pathways Involving Amino Acid Position 143 of HIV-1 Integrase Are Preferentially Associated with Specific Secondary Amino Acid Substitutions and Confer Resistance to Raltegravir and Cross-Resistance to Elvitegravir
    Huang, Wei
    Frantzell, Arne
    Fransen, Signe
    Petropoulos, Christos J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (09) : 4105 - 4113
  • [2] Substitutions at Amino Acid Positions 143, 148, and 155 of HIV-1 Integrase Define Distinct Genetic Barriers to Raltegravir Resistance In Vivo
    Fransen, Signe
    Gupta, Soumi
    Frantzell, Arne
    Petropoulos, Christos J.
    Huang, Wei
    JOURNAL OF VIROLOGY, 2012, 86 (13) : 7249 - 7255
  • [3] 4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-Containing Compounds Having High Potency against Raltegravir-Resistant Integrase Mutants of HIV-1
    Zhao, Xue Zhi
    Smith, Steven J.
    Metifiot, Mathieu
    Marchand, Christophe
    Boyer, Paul L.
    Pommier, Yves
    Hughes, Stephen H.
    Burke, Terrence R., Jr.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (12) : 5190 - 5202
  • [4] Bicyclic 4-amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing compounds having high potency against Raltegravir-resistant integrase mutants of HIV-1
    Zhao, Xue Zhi
    Smith, Steven J.
    Metifiot, Mathieu
    Marchand, Christophe
    Pommier, Yves
    Hughes, Stephen H.
    Burke, Terrence R., Jr.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [5] 4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-Containing Compounds Having High Potency against Raltegravir-Resistant Integrase Mutants of HIV-1 (vol 57, pg 5190, 2014)
    Zhao, Xue Zhi
    Smith, Steven J.
    Metifiot, Mathieu
    Marchand, Christophe
    Boyer, Paul L.
    Pommier, Yves
    Hughes, Stephen H.
    Burke, Terrence R., Jr.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (15) : 6885 - 6885
  • [6] Impact of HIV-1 gp41 amino acid substitutions (positions 36-45) on susceptibility to T-20 (enfuvirtide) in vitro:: analysis of primary virus isolates recovered from patients during chronic enfuvirtide treatment and site-directed mutants in NL4-3
    Mink, M
    Greenberg, M
    Moiser, S
    Janumpalli, S
    Davison, D
    Jin, L
    Melby, T
    Sista, P
    Lambert, D
    Cammack, N
    Salgo, M
    Matthews, T
    ANTIVIRAL THERAPY, 2002, 7 : S24 - S24
1